Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human VEGF R2 / KDR Protein (HPLC-verified), His Tag, 100µg  

Recombinant Human VEGF R2 / KDR Protein (HPLC-verified), His Tag, 100µg

Recombinant Human VEGF R2 / KDR Protein (HPLC-verified) (Human VEGF R2, His Tag) Ala 20 - Glu 764, produced in human 293 cells (HEK293), His Tag

Synonym: recombinant human protein, KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor

More details

KDR-H5227-100

Availability: within 7 days

348,00 €

Background
Kinase insert domain receptor (KDR) also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo).[1-3] In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi\'s sarcoma lesions.

Source
Human VEGF R2, His Tag (HPLC-verified) (KDR-H5227) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 764 (Accession # AAI31823.1).
Predicted N-terminus: Ala 20
Request for sequence

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 85.2 kDa. The protein migrates as 125-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Human VEGF R2, His Tag (HPLC-verified) (Cat. No. KDR-H5227) ELISA bioactivity
Immobilized Human VEGF165, Tag Free (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Human VEGF R2, His Tag (Cat. No. KDR-H5227) with a linear range of 10-156 ng/mL (QC tested).

References

(1) Holmes K,et al. (2007) . Cell Signal. 19 (10): 2003–2012.
(2) Stuttfeld E, et al. (2009). IUBMB Life 61 (9): 915–22.
(3) Fujita, N, et al. (2008). Biochemical and biophysical research communications 372 (2): 367–372.